Biogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®)
Biogen (NASDAQ: BIIB) will present data from its Alzheimer’s disease programs at the Alzheimer's Association International Conference® 2017 (AAIC®) in London, July 16 - 20, 2017.
The planned poster presentations include:
Change from Baseline in Clinical Dementia Rating Scale Cognitive
and Functional Domains in PRIME, a Randomized Phase 1b Study of the
Anti-Amyloid Beta Monoclonal Antibody Aducanumab (BIIB037). Poster
1-053: July 16, 2017, 9:30 a.m. GMT+1. This new post-hoc analysis
shows the change in the cognitive and functional subscores, which are
derived from the previously reported clinical dementia rating (CDR)
score for the overall and early Alzheimer’s disease populations in the
1, 3, 6 and 10 mg/kg aducanumab fixed-dosing cohorts in Phase 1b.
This poster will be available concurrently with the session on the Investors section of the Biogen company website, www.Biogen.com.
- Signs and Symptoms of Alzheimer’s Disease Noted in Health Records up to 5 Years Prior to Diagnosis . Poster 2-275: July 17, 2017, 9:30 a.m. GMT+1. This analysis reports the documentation of cognitive and behavioral impairment from U.S. medical health records, prior to an Alzheimer’s disease diagnosis.
Aducanumab (BIIB037) is an investigational compound being developed for the treatment of early Alzheimer’s disease. Aducanumab is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune’s technology platform called Reverse Translational Medicine (RTM). Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook and YouTube.
Biogen Safe Harbor
This press release contains forward-looking statements, including statements relating to the development and potential benefits, safety and efficacy of investigational drugs, including aducanumab and results of certain clinical studies. These statements may be identified by words such as “believe,” “except,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on our current beliefs and expectations. You should not place undue reliance on these statements or the scientific data presented. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Factors which could cause actual results to differ materially from our current expectations include the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected, unexpected concerns may arise from additional data or analysis, including data, analysis or results obtained during our clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates, or we may encounter other unexpected hurdles which may be impacted by, among other things, the occurrence of adverse safety events, failure to obtain regulatory approvals in certain jurisdictions, failure to protect intellectual property and other proprietary rights, product liability claims, third party collaboration risks, and the other risks and uncertainties that are described in the Risk Factors section of Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
The Geneva Association: Insurance Industry Taking Action in Addressing Climate Change, Although External Hurdles Remain22.1.2018 10:00 | Pressemelding
The insurance industry is contributing significantly to building socio-economic resilience to climate change and supporting the transition to a low-carbon economy in their role as risk management experts and investors, although a number of challenges are hindering the industry’s efforts to scale up its contribution, according to a new research report from The Geneva Association, the leading international think tank of the insurance industry. The report ‘Climate Change and the Insurance Industry: Taking Action as Risk Managers and Investors’ is based on interviews with 62 C-level executives of globally active insurance and reinsurance companies, and offers insights into the role of the insurance industry in addressing climate change adaptation and mitigation. Anna Maria D’Hulster, Secretary General of The Geneva Association, commented: “The study has confirmed that climate change is a topic that has made its way up to the boardrooms of the insurance industry, although insurers are neith
Yonnic GmbH Enriches Targeting for Clients with Digital Element’s IP Geolocation Data22.1.2018 09:03 | Pressemelding
Leading IP geolocation intelligence company, Digital Element, has today announced that Yonnic GmbH, the industry pioneer of performance marketing solutions, has chosen its NetAcuity technology to boost targeting efficiency for its clients. Yonnic delivers brand relevance for its clients by uncovering and converting consumer intent through its proprietary process Intent-Based Planning tool. Its core application, CloudTDS, provides traffic routing and content delivery based upon a wide range of customisable rules and settings, such as geographical targeting and device specific targeting. By incorporating Digital Element’s NetAcuity data into its solution, Yonnic is able to upgrade its geographical targeting to provide the most accurate solution to its clients. Adding additional IP intelligence datasets such as connection speed, mobile carrier, internet service provider and whether a home or business connection is being used enables Yonnic to further boost its targeting and analytics capa
Vertex Hires Regional Leader to Expand European Presence22.1.2018 08:53 | Pressemelding
Vertex, Inc., a leading provider of tax automation solutions, announced Akram El-Rikabi has joined the management team as the regional leader to head European operations. This announcement reflects the company’s growing global presence in the European marketplace and dedication to the international business community. Vertex Vice President of Global Business Development Rebecca Polley states, “Having a proven leadership team and strong regional presence in Europe is critical to engaging with our multinational clients, prospects and partners. In his role, Akram will support Vertex’s growth initiatives by leveraging his expertise in helping customers realize strategic value in their technology investments, especially in the increasingly complex global tax landscape.” El-Rikabi brings 20 years of experience in finance, economics, banking, global partnerships and software management, having worked with global corporations in over 20 countries. Most recently, El-Rikabi was the regional sale
Octapharma: Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A22.1.2018 08:00 | Pressemelding
Octapharma is delighted to announce the publication of final data from a Good Clinical Practice (GCP) trial in PUPs in the internationally renowned medical journal Haemophilia. The study assessed the immunogenicity, efficacy, safety and tolerability of octanate® in PUPs with severe haemophilia A. PUPs with haemophilia A are at greatest risk of inhibitor development. Approximately 35% develop inhibitors, which are associated with detrimental health and economic consequences. In this prospective, multinational study, 51 PUPs with severe haemophilia A received octanate® exclusively as replacement therapy, either prophylactically or for on-demand treatment of bleeds, for a total of 100 exposure days (EDs) or 5 years. Five (9.8%) of the 51 patients developed inhibitors, 4 (7.8%) of which were high titre (≥5 BU/mL) and 1 low titre (<5 BU/mL). All inhibitors developed during on-demand treatment and all 4 high-titre inhibitors developed within the first 20 EDs. All patients who developed inhib
Alkemics to Power productDNA:Hub – an Industry-Led Service to Help Retailers and Suppliers Share Product Data and Images22.1.2018 08:00 | Pressemelding
A group of leading UK grocery retailers and suppliers facilitated by GS1 UK, the product data standards organisation, has selected Alkemics to power productDNA:hub, the new service that helps retailers and suppliers to share and manage product data and images. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122005133/en/ The Alkemics platform that will power productDNA:hub (Photo: Alkemics) Alkemics is a French software platform that facilitates product data sharing between brands and retailers, allowing them to collect and enrich their product data. After a selection phase that included the testing of 25 international solution providers, Alkemics was chosen by the group of leading UK retailers and suppliers to power the collection, standardisation, and sharing of product data among manufacturers, brands, and retailers in the UK. Starting in the spring of 2018, several leading British retailers and brands will use the Alkem
Astrata Launches VanLinc™, for Intelligent LCV Fleet Management22.1.2018 07:45 | Pressemelding
After more than 25 years developing high-end telematics software for the HGV industry globally, Astrata is now bringing its expertise to benefit the European LCV market with the launch of VanLinc™. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180121005105/en/ VanLinc Main Visual (Photo: Business Wire) This easy-to-use, comprehensive fleet management solution provides real-time insights on drivers, vehicles and other assets, helping businesses drive productivity and increase capacity for work. Unlike other products, it seamlessly integrates with other business systems for joined-up working and improved efficiencies. Businesses with services reliant on vehicles now have the ability to maximise operational efficiencies due to one solution communicating with all other business systems. The VanLinc solution also effortlessly integrates with refrigeration systems to maintain constant temperature control during transport. The LCV
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom